Emtricitabine and tenofovir disoproxil fumarate

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Johns Hopkins University, Philadelphia Fight

Conditions

HIVHIV InfectionHIV InfectionsHepatitis C

Phase 2

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

CompletedNCT00551018

Merck Sharp & Dohme LLCHIV Infections

Start: 2007-12-31End: 2010-10-31Updated: 2015-02-06

Phase 4

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

CompletedNCT01285050

Johns Hopkins UniversityHepatitis C, HIV Infection

Start: 2011-01-31End: 2015-04-30Updated: 2016-11-29

Unknown Phase

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

CompletedNCT02367807

Philadelphia FightHIV

Start: 2015-02-28End: 2016-08-31Updated: 2016-10-11

Related Papers

Decreased Activated CD4 <sup>+</sup> T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 <sup>+</sup> T Cell Recovery

Viral Immunology2021-10-212 citations

Presence of Human Hepegivirus-1 in a Cohort of People Who Inject Drugs.

2017-06-0629 citations

Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.

2017-06-0113 citations